Skip to main content
SpringerLink
Log in

The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro

  • Original Article
  • Published:
Modern Rheumatology

Abstract

The inducible prostaglandin synthesis enzyme, cyclooxygenase-2 (COX-2), is involved in bone resorption and osteoclastogenesis, and acts indirectly through prostaglandin E2 (PG E2) produced by osteoblastic cells. This study was undertaken to investigate whether celecoxib (a selective COX-2 inhibitor) has a direct effect on human osteoclast precursors to influence osteoclastogenesis in vitro. Human peripheral blood mononuclear cells (PBMCs) were cultured on glass coverslips and dentine slices with soluble receptor activator of NF-kB ligand (sRANKL) and macrophage colony stimulating factor (M-CSF). COX inhibitors including celecoxib were added to the cultures. Osteoclast formation was assessed as the number of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells (MNCs), and the functional evidence of lacunar resorption pits on dentine slices was assessed. Celecoxib and indomethacin inhibited osteoclast formation and the extent of lacunar resorption in a dose-dependent manner, but the effect of indomethacin was less than that of celecoxib. Mofezolac affected neither the number of TRAP-positive MNCs nor the extent of lacunar resorption pits. These results indicate that celecoxib influences not only osteoclast formation through osteoblastic cells but also acts directly on circulating osteoclast precursors to influence human osteoclast differentiation. The effect of celecoxib on osteoclast precursors may be related to the COX-2 signal pathway.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Feyen JHM, van der Wilt G, Moonen P, et al. Stimulation of arachidonic acid metabolism in primary cultures of osteoblast-like cells by hormones and drug. Prostaglandins. 1984;28:213–20.

    Article  Google Scholar 

  2. Harrison JR, Lorenzo JA, Kawaguchi H, et al. Stimulation of prostaglandin E2 production by interleukin-1α and transforming growth factor α in osteoblastic MC3T3-E1 cells. J Bone Miner Res. 1994;9:817–23.

    Article  PubMed  CAS  Google Scholar 

  3. Rodan SB, Rodan GA, Simmons HA, et al. Bone resorptive factor produced by osteosarcoma cells with osteoblastic features is PG E2. Biochem Biophys Res Common. 1981;102:1358–65.

    Article  CAS  Google Scholar 

  4. Fletcher BS, Kujubu DA, Perrin DM, et al. Structure of the mitogen-inducible TIS10 gene and demonstration that TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem. 1992;267:4338–44.

    PubMed  CAS  Google Scholar 

  5. Kujubu DA, Fletcher BS, Varnum BC. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cell, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991;266:12866–72.

    PubMed  CAS  Google Scholar 

  6. Vane J. Towards a better aspirin. Nature. 1994;367:215–6.

    Article  PubMed  CAS  Google Scholar 

  7. Xie WL, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA. 1991;88:2692–6.

    Article  PubMed  CAS  Google Scholar 

  8. Khanna IK, Weier RM, Yu Y. 1, 2-Diarylimidazoles as potent and selective inhibitors of cyclooxygenase-2. J Med Chem. 1997;40:1619–33.

    Article  PubMed  CAS  Google Scholar 

  9. Khanna IK, Weier RM, Yu Y, et al. 1, 2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active anti-inflammatory agents. J Med Chem. 1997;40:1634–47.

    Article  PubMed  CAS  Google Scholar 

  10. Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1, 5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzene sulfonamide (SC-58635, celecoxib). J Med Chem. 1997;40:1347–65.

    Article  PubMed  CAS  Google Scholar 

  11. Zhang Y, Shaffer A, Portanova J, et al. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther. 1997;283:1069–75.

    PubMed  CAS  Google Scholar 

  12. Lanza FI, Rack MF, Callison DA. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a novel COX-2 selective inhibitor. Gastroenterology. 1997;112:194.

    Google Scholar 

  13. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 1998;41:1591–602.

    Article  PubMed  CAS  Google Scholar 

  14. Simon LS, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized control trial. JAMA. 1999;282:1921–8.

    Article  PubMed  CAS  Google Scholar 

  15. Zhao SZ, Hatoum HT, Hubbard RC, et al. Effect of celecoxib, a novel COX-2 inhibitor, on health-related quality of life patients with osteoarthritis of the knee. Arthritis Rheum. 1997;40:S88.

    Google Scholar 

  16. Geis GS, Hubbard RC, Callison D, et al. Safety and efficacy of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum. 1998;41:S364.

    Google Scholar 

  17. Hubbard RC, Koepp RJ, Yu S. SC-58635 (celecoxib), a novel COX-2 selective inhibitor, is effective as a treatment for osteoarthritis (OA) in a short-term pilot study. Arthritis Rheum. 1996;39:S226.

    Article  Google Scholar 

  18. Hubbard RC, Geis GS, Woods E, et al. Efficacy, tolerability, and safety of celecoxib, a specific COX-2 inhibitor, in osteoarthritis. Arthritis Rheum. 1998;41:S196.

    Google Scholar 

  19. Igarashi K, Woo JT, Stern PH. Effects of a selective cyclooxygenase-2 inhibitor, celecoxib, on bone resorption and osteoclastgenesis in vitro. Biochem Pharmacol. 2002;63:523–32.

    Article  PubMed  CAS  Google Scholar 

  20. Im GI, Kwon BC, Lee KB. The effect of COX-2 inhibitors on periprosthetic osteolysis. Biomaterials. 2004;25:269–75.

    Article  PubMed  CAS  Google Scholar 

  21. Ono K, Akatsu T, Murakami T, et al. Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. J Bone Miner Res. 2002;17:774–81.

    Article  PubMed  CAS  Google Scholar 

  22. Zhang X, Morham SG, Langenbach R, et al. Evidence for a direct role of cyclo-oxygenase 2 in implant wear debris-induced osteolysis. J Bone Miner Res. 2001;16:660–70.

    Article  PubMed  CAS  Google Scholar 

  23. Tsuboi H, Nampe A, Matsui Y, et al. Celecoxib prevents juxta-articular osteopenia and growth plate destruction adjacent to inflamed joints in rats with collagen-induced arthritis. Mod Rheumatol. 2007;17:115–22.

    Article  PubMed  CAS  Google Scholar 

  24. Okada Y, Pilbeam C, Raisz L, et al. Role of cyclooxygenase-2 in bone resorption. J UOEH. 2003;25:185–95.

    PubMed  CAS  Google Scholar 

  25. Fujikawa Y, Quinn JM, Sabokbar A, et al. The human osteoclast precursor circulates in the monocyte fraction. Endocrinology. 1996;137:4058–60.

    Article  PubMed  CAS  Google Scholar 

  26. Taira H, Fujikawa Y, Kudo O, et al. Menatetrenone (vitamin K2) acts directly on circulating human osteoclast precursors. Calcif Tissue Int. 2003;73:78–85.

    Article  PubMed  CAS  Google Scholar 

  27. Takita C, Fujikawa Y, Itonaga I, et al. Infliximab acts directly on human osteoclast precursors and enhances osteoclast formation induced by receptor activator of nuclear factor kappaB ligand in vitro. Mod Rheumatol. 2005;15:97–103.

    Article  PubMed  CAS  Google Scholar 

  28. Matsuzaki K, Udagawa N, Takahashi N, et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun. 1998;246:199–204.

    Article  PubMed  CAS  Google Scholar 

  29. Quinn JN, Elliott J, Gilliespie MT, et al. A combination of osteoclast differentiating factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology. 1998;139:4424–7.

    Article  PubMed  CAS  Google Scholar 

  30. Davies NM, McLachlan AJ, Day RO, et al. Clinical pharmacokinetics and pharmacodynamics of celecoxib. Clin Pharmacokinet. 2000;38:225–42.

    Article  PubMed  CAS  Google Scholar 

  31. Han SY, Lee NK, Kim KH, et al. Transcriptional induction of cyclooxygenase-2 in osteoclast precursors is involved in RANKL-induced osteoclastogenesis. Blood. 2005;15:1240–5.

    Article  CAS  Google Scholar 

  32. Fu JY, Masferrer JL, Seibert K, et al. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem. 1990;265:16737–40.

    PubMed  CAS  Google Scholar 

  33. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA. 1992;89:7384–8.

    Article  PubMed  CAS  Google Scholar 

  34. Stamp L, James MJ, Cleland LG. Paracrine upregulation of monocyte cyclooxygenase-2 by mediators produced by T lymphocytes: role of interleukin 17 and interferon-γ. J Rheumatol. 2004;31:1246–54.

    PubMed  CAS  Google Scholar 

  35. Inoue Y, Otsuka T, Niiro H, et al. Novel regulatory mechanisms of CD40-induced prostanoid synthesis by IL-4 and IL-10 in human monocytes. J Immunol. 2004;172:2147–54.

    PubMed  CAS  Google Scholar 

  36. Ono K, Akatsu T, Kugai N, et al. The effect of deletion of cyclooxygenase-2, prostaglandin receptor EP2, or EP4 in bone marrow cells on osteoclasts induced by mouse mammary cancer cell lines. Bone. 2003;33:798–804.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita, 879-5593, Japan

    Masayuki Kawashima, Yosuke Fujikawa, Ichiro Itonaga, Chikahiro Takita & Hiroshi Tsumura

Authors
  1. Masayuki Kawashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yosuke Fujikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ichiro Itonaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chikahiro Takita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroshi Tsumura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masayuki Kawashima.

About this article

Cite this article

Kawashima, M., Fujikawa, Y., Itonaga, I. et al. The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro. Mod Rheumatol 19, 192–198 (2009). https://doi.org/10.1007/s10165-008-0149-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-008-0149-6

Keywords

Search

Navigation